Matching articles for "Tobacco dependence"
Drugs for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • July 15, 2019; (Issue 1576)
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral...
Smoking tobacco remains the primary preventable
cause of death in the US. Smoking cessation often requires
both pharmacotherapy and behavioral support.
Expanded Table: Some Drugs for Smoking Cessation (online only)
The Medical Letter on Drugs and Therapeutics • July 15, 2019; (Issue 1576)
...
View the Expanded Table: Some Drugs for Smoking Cessation
Drugs for COPD
The Medical Letter on Drugs and Therapeutics • April 10, 2017; (Issue 1518)
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated...
The main goals of treatment for chronic obstructive
pulmonary disease (COPD) are to relieve symptoms,
reduce the frequency and severity of exacerbations,
and prevent disease progression. Updated guidelines
for treatment of COPD have been published in
recent years.
Drugs for Tobacco Dependence
The Medical Letter on Drugs and Therapeutics • February 29, 2016; (Issue 1489)
Tobacco dependence remains the primary preventable
cause of death in the United States. It is a chronic
disorder that often requires pharmacologic therapy,
but counseling may be equally effective and can add...
Tobacco dependence remains the primary preventable
cause of death in the United States. It is a chronic
disorder that often requires pharmacologic therapy,
but counseling may be equally effective and can add to
the effectiveness of any treatment for this indication.
Abrupt cessation of smoking appears to be as effective
as gradual reduction.
Electronic Cigarettes
The Medical Letter on Drugs and Therapeutics • November 11, 2013; (Issue 1429)
Electronic cigarettes, also called e-cigarettes, are advertised
as a safer, more convenient, and socially acceptable
alternative to smoking tobacco cigarettes. Widely
available in retail stores and on the...
Electronic cigarettes, also called e-cigarettes, are advertised
as a safer, more convenient, and socially acceptable
alternative to smoking tobacco cigarettes. Widely
available in retail stores and on the Internet, their use
has been increasing over recent years, primarily among
smokers, but also among non-smokers.
Electronic Cigarettes for Smoking Cessation
The Medical Letter on Drugs and Therapeutics • November 26, 2012; (Issue 1404)
Electronic cigarettes, also called e-cigarettes, are
battery-operated nicotine-delivery devices that
resemble tobacco cigarettes. They deliver vapor containing
a mixture of nicotine and either propylene...
Electronic cigarettes, also called e-cigarettes, are
battery-operated nicotine-delivery devices that
resemble tobacco cigarettes. They deliver vapor containing
a mixture of nicotine and either propylene glycol
or glycerol. E-cigarettes are widely available in
retail stores and on the internet in labeled strengths
ranging from zero to high levels of nicotine and in flavors
such as tobacco, mint, coffee, cherry, bubblegum,
and chocolate. They are advertised as a healthier
alternative to smoking a tobacco cigarette and,
although not FDA-approved, as a smoking cessation
tool.
Drugs for Chronic Obstructive Pulmonary Disease
The Medical Letter on Drugs and Therapeutics • November 1, 2010; (Issue 99)
The goals of drug therapy for chronic obstructive pulmonary
disease (COPD) are to reduce symptoms such
as dyspnea, improve exercise tolerance and quality of
life, and decrease complications of the disease...
The goals of drug therapy for chronic obstructive pulmonary
disease (COPD) are to reduce symptoms such
as dyspnea, improve exercise tolerance and quality of
life, and decrease complications of the disease such as
acute exacerbations. Other guidelines for treatment of
this condition have been published or updated in
recent years.
Safety of Smoking Cessation Drugs
The Medical Letter on Drugs and Therapeutics • August 24, 2009; (Issue 1319)
The most effective drugs available for treatment of tobacco dependence are bupropion (Zyban, and others and varenicline (Chantix). The FDA recently ordered the manufacturers of both to add boxed warnings about...
The most effective drugs available for treatment of tobacco dependence are bupropion (Zyban, and others and varenicline (Chantix). The FDA recently ordered the manufacturers of both to add boxed warnings about the risk of psychiatric symptoms and suicide to their prescribing information (FDA Alert, 7/1/2009).
Drugs for Tobacco Dependence
The Medical Letter on Drugs and Therapeutics • September 1, 2008; (Issue 73)
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking...
Peptic ulcers caused by treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) are mainly gastric ulcers. The greater the number of office visits and the longer the counseling time, the higher the smoking cessation rates have been.
Varenicline (Chantix) Warnings: Risk Versus Benefit
The Medical Letter on Drugs and Therapeutics • July 14, 2008; (Issue 1290)
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about...
The nicotine receptor partial agonist varenicline (Chantix - Pfizer) appears to be the most effective drug available to treat tobacco dependence, but the FDA has added a warning to the package insert about neuropsychiatric symptoms and exacerbations of preexisting psychiatric illness associated with its use. Agitation, hostility, depressed mood, suicidal ideation and suicidal behavior have been reported as postmarketing adverse events in patients who took varenicline and stopped smoking and in those who took the drug and continued to smoke.
Drugs for Chronic Obstructive Pulmonary Disease
The Medical Letter on Drugs and Therapeutics • November 1, 2007; (Issue 63)
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such...
The goals of drug therapy for chronic obstructive pulmonary disease (COPD) are to reduce symptoms such as dyspnea, improve exercise tolerance and quality of life, and minimize complications of the disease such as acute exacerbations and cor pulmonale. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines developed by the World Health Organization and the National Heart, Lung and Blood Institute were updated in 2006. The American Thoracic Society and the European Respiratory Society jointly developed guidelines for COPD in 2004.
Varenicline (Chantix) for Tobacco Dependence
The Medical Letter on Drugs and Therapeutics • August 14, 2006; (Issue 1241)
Varenicline tartrate (Chantix - Pfizer) is now available for oral treatment of tobacco dependence. Some other drugs for this indication are listed in this...
Varenicline tartrate (Chantix - Pfizer) is now available for oral treatment of tobacco dependence. Some other drugs for this indication are listed in this article.
Drugs for Tobacco Dependence
The Medical Letter on Drugs and Therapeutics • June 1, 2003; (Issue 10)
Tobacco dependence is a chronic illness that may require pharmacological treatment (MC Fiore et al, JAMA 2000; 283:3244; DPL Sachs in JE Hodgkin et al, eds, Pulmonary Rehabilitation: Guidelines to Success, 3rd...
Tobacco dependence is a chronic illness that may require pharmacological treatment (MC Fiore et al, JAMA 2000; 283:3244; DPL Sachs in JE Hodgkin et al, eds, Pulmonary Rehabilitation: Guidelines to Success, 3rd ed, Philadelphia; Lippincott Williams & Wilkins, 2000, page 261).